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Abstract: Glycogen-rich clear cell carcinoma (GRCC) is a very
rare form of primary breast cancer (< 0.1% of all breast cancers).
It is characterized by the presence of neoplastic cells with a
glycogen-abundant clear cytoplasm (the Periodic Acid Schiff–
positive, diastase-sensitive). The expression of steroid receptors
(estrogen and progesterone receptors) has been variably reported
(35% to 100% of the cases), whereas most studies reported low
human epidermal growth factor receptor 2 positivity in GRCC.
High androgen receptor positivity without androgen receptor
splice variant-7 was reported in one recent study. Although
sparse, the preliminary theranostic data on GRCC indicate the
potential of targeted treatments in selected cases (antiandrogen,
PIK3CA, and immune checkpoint inhibitors). Because of its
rarity, the prognosis for GRCC patients remains controversial.
Herein, we comprehensively appraise the epidemiological, mor-
phologic, molecular, and clinical characteristics of this rare
mammary malignancy.
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Invasive breast carcinoma (IBC) is not one disease, butrather a heterogenous group of diseases, most of which
possess a distinct morphology, molecular features, and clinical
behavior.1 Irrespective of the morphology, all IBC are grouped
into the following biomarker-deﬁned subtypes on the basis of
estrogen receptor (ER) and ERBB2 [human epidermal growth
factor receptor (HER) 2] status: ER-positive/HER2-negative
(luminal A); ER-positive/HER2-positive (luminal B); ER-
negative/HER2-positive (HER2+ subtype); and ER-negative/
HER2-negative [triple-negative breast cancer (TNBC)/
subtype].2
The term IBC of no special type (NST) refers to a
large and heterogeneous group of IBCs that cannot be
classiﬁed morphologically as any of the special histologic
types.2 IBC-NST is the most common morphologic subtype,
whereas all other subtypes (= special histologic types) constitute
∼20% of all IBC.
Among the IBC-NST, several distinct morphologic
patterns have been recognized including oncocytic, sebaceous,
lipid-rich, and glycogen-rich/clear cell (GRCC) patterns.2
In addition, the most recent World Health Organization
(WHO) classiﬁcation acknowledged carcinomas with medul-
lary, neuroendocrine, pleomorphic, osteoclast-like giant cells,
choriocarcinomatous, and melanocytic features/patterns to be
the spectrum of IBC-NST morphologies. Consequently, these
cancers do not require the 90% rule for differentiation, which
is applied for special histologic types.2
In the current review, we focus on the GRCC form
of IBC-NST, providing its epidemiological, morphologic,
ultrastructural, molecular, radiologic, and clinical char-
acteristics.
DEFINITION
GRCC is a morphologic pattern of IBC-NST that is
composed of neoplastic cells with abundant clear cytoplasm
that contains glycogen.2 Given that cytoplasmic glycogen may
be seen without a marked clear cell appearance and because
clear cell morphology can be caused by substances other than
glycogen, both features are required for the diagnosis of this
speciﬁc pattern.2 Notably, Hull et al3 were the ﬁrst to introduce
and elucidate this peculiar entity in 1981.
Clear cell changes may also affect normal and benign
breast tissues. Thus, breast ducts and lobules may undergo
clear changes during the pregnancy, where the clearing of
the cytoplasm typically affects myoepithelial cells and the
clearing of the cytoplasm that may be seen in benign
changes such as apocrine metaplasia.4
EPIDEMIOLOGY OF GRCC
The actual incidence of GRCC is unknown, but most
authors agree that it is a very uncommon pattern of IBC-NST.
The largest to date study, based on the analysis from the
Surveillance, Epidemiology and End Results (SEER) database,
identiﬁed 155 cases of GRCC among the 1,251,584 cases of
other (non-GRCC) breast carcinomas (frequency ∼0.01%).5 A
study of Toikkanen and Joensuu6 revealed 6 cases of GRCC
among the 439 cases of IBCs (∼1.4%); a similar incidence
(1.8%) was reported by Nacul et al,7 whereas Kuroda et al8
reported 20 cases of GRCC among the 723 consecutive
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patients with primary breast carcinomas (∼2.8%). Our own
experience also indicates a very low incidence of GRCC
(∼0.2%).
We conducted a comprehensive literature survey
(PubMed/MEDLINE, Scopus, Web of Science) that revealed
a vast majority of publications being single cases (case reports)
and small case series (<20 cases per study) (Tables 1, 2). We
found only 6 larger studies reporting > 20 GRCC cases
(Table 1).
HISTOLOGIC AND ULTRASTRUCTURAL
FEATURES OF GRCC
Similar to IBC-NST, most GRCCs exhibit a sheet-like,
nested, or corded growth pattern14 (Fig. 1). Occasionally, the
clear cells may be arranged in solid, papillary, micropapillary,
cribriform, alveolar, lobular, and/or tubular patterns.3,14,20–24
Rare cases of neuroendocrine, apocrine, and mucinous
differentiation have also been well documented.14,21,25
Most GRCC are diagnosed as invasive carcinomas.
Rare cases of pure intraductal GRCC have also been
described.26,27
The cancer cells of GRCC have well-deﬁned borders
with polygonal contours (Fig. 1).28 The cytoplasm that is
clear or ﬁnely granular contains the Periodic Acid Schiff
(PAS)-positive, diastase-sensitive glycogen.29 The cell nuclei
are oval our round, with a clumped chromatin and
prominent nucleoli (Fig. 1). The nuclear atypia is usually
moderate to marked,14,28,30,31 which corresponds to grade 2
or 3 according to the Nottingham histologic score.
Seminal papers of Hull and colleagues3,15 revealed
the ultrastructural features of GRCC. According to Hull
et al,15 neoplastic clear cells contain large quantities of
“non–membrane-bound particulate glycogen and that
formed numerous acini.” On the apical site, the clear cells
form microvilli while tight junctions and desmosomes are
created on lateral sides. The intracellular content is typi-
cally PAS and digested with diastase, which is consistent
with glycogen pools. These ﬁndings were further con-
ﬁrmed in subsequent studies of Fisher et al,16 Okamoto,23
Alexiev,30 and Fujino et al.22
DIFFERENTIAL DIAGNOSIS
Several breast cancers with clear cell cytoplasm should
be considered in the differential diagnosis. Among these, lipid-
rich carcinoma, sebaceous carcinoma, secretory carcinoma,
histiocytoid carcinoma, and myoepithelial tumors should be
ruled out.2,32 In addition, apocrine carcinomas may also
contain cells with foamy or clear cytoplasm (“type B” cells).33
Focal clear cell changes may also be encountered in other
growth patterns of IBC including papillary, micropapillary,
TABLE 1. Summary of the Published Studies (>5 Cases/Patients) That Reported Steroid Receptor Profile, HER2 Status, and/or
Follow-up Data on the Patients With Glycogen-rich Clear Cell Carcinoma
References No. Patients (Cases) ER/PR/HER2 Status (%) Clinical Outcome (Survival)
Skenderi et al9* 9 88/88/0 Not reported
Zhou et al5 155 (SEER) 46.5/27/6.9 Worse than NST
Chang et al10 5 100/0/0 Not reported
Ma et al11 28 61.5/12 Similar to NST
Nacul et al7 17 NA Similar to NST (early stage)
Akbulut et al12 37 62/43/44 Not reported
Kuroda et al8 20 35/30/20 5/15 died of disease
Varga et al13 12 75/75/25 2/3 positive axillary lymph nodes
Hayes et al14 13 57/0/NA 3/13 died of the disease
Toikkanen and Joensuu6 6 NA Worse than NST (33% 5 y survival)
Hull and Warfel15 10 NA (ultrastructural study) 5/10 died of the disease
Fisher et al16 45 NA Worse than NST
*This is the only molecular genetic study on glycogen-rich clear cell carcinoma.
ER indicates estrogen receptor; HER2, human epidermal growth factor receptor 2; NA, not available; NST, no special type; PR, progesterone receptor; SEER,
Surveillance, Epidemiology and End Results database.
TABLE 2. Summary of the Published Molecular Studies on Glycogen-rich Clear Cell Carcinoma
References No. Patients (Cases) Method(s) Molecular Features (Number of Positive/Total Number of Cases)
Skenderi et al9 9 IHC, ISH, NGS AR+ (7/9), ARv7+ (0/7), PD-L1+ (3/8), PIK3R1 (1/5), PTEN (3/8), BRCA2 (1/5),
TP53 (1/5), CDKN2A (1/5), BCOR (1/5), MSI-S (8/8)
Chang et al10 5 IHC HepPar1+ (5/5), GATA3+ (5/5), AFP− (5/5)
Levva et al17 1 qPCR, IHC, FISH EGFR mutated (p.Asp1084Asn) and ampliﬁed; p53+, CK5−, low Ki-67
Kim et al18 3 IHC p53+ (1+/3); Ki-67 (15-60%), E-cadherin (2+/3), AR (1+/3), p63 (1+/3), cKit (2+/3),
EGFR (2+/3), GCDFP-15 (0/3), Galectin-3 (2+/3)
Varga and Caduff19 6 IHC and TUNEL Low proliferation rate (Ki-67) and low apoptotic rate
Toikkanen and Joensuu6 6 Flow cytometry Nondiploid cancers with a high S-phase fraction
AFP indicates alpha-fetoprotein; AR, androgen receptor; EGFR, epidermal growth factor receptor; FISH, ﬂuorescence in situ hybridization; GCDFP-15, gross cystic
disease ﬂuid protein 15; IHC, immunohistochemistry; ISH, in situ hybridization; MSI-S, microsatellite instability stable; NGS, next-generation sequencing; PD-L1,
programmed death receptor ligand 1; qPCR, quantitative polymerase chain reaction; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.
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mucinous, and neuroendocrine carcinomas. Rarely, benign
and malignant myoepithelial lesions of the breast may have
prominent clear cell differentiation and should be differ-
entiated from GRCC.34–36 Govender et al37 described an
exceptional case of a primary clear cell “sugar” tumor of the
breast in a 16-year-old girl. These tumors belong to a broader
family of perivascular epithelioid cell tumors that were origi-
nally described in the lung and later at several extrapulmonary
sites (eg, kidneys, gastrointestinal tract, uterus).37,38 Several
additional cases of perivascular epithelioid cell tumors of the
breast have been well documented.39–41
In most of these cases, special stains (PAS and PAS-
diastase) along with an appropriate immunohistochemical
algorithm are helpful to conﬁrm the presence of intra-
cytoplasmic glycogen and to render the correct diagnosis.
In case of secretory carcinoma, the detection of speciﬁc
chromosomal translocation t(12;15)(p13;q25), resulting in
the ETV6-NTRK3 fusion gene, rules out the GRCC.42
Although nonprimary cancers with clear cell histology
involving the breast (eg, metastatic clear cell renal cell carci-
noma, melanomas, and soft tissue tumors with clear cell
morphology) are extremely rare, they should also be consid-
ered in the differential diagnosis. In all these cases, the clinical
history of the primary site along with a meticulous im-
munohistochemical panel may lead to the correct diagnosis.
STEROID RECEPTORS IN GRCC
ER positivity has been reported in 35% to 100% of cases,
whereas the PR positivity appears to be markedly lower (range
in the reported studies 0% to 88%; most of the reported studies
reported PR positivity <30%) (Table 1). This is in line with the
data from the SEER database, where the ER positivity rate in
GRCC was ∼47% and 27% for PR.5
The expression of androgen receptor (AR) was re-
cently reported in 88% of GRCC cases.9 Notably, none of
the AR-positive GRCC harbored androgen receptor splice
variant-7 (ARv7) (Table 2). ARv7 encodes a truncated AR
protein that lacks the ligand-binding domain and is
constitutively active in the absence of androgens.43
HER RECEPTORS FAMILY IN GRCC
HER2 expression in GRCC has been variably reported
in the literature (Table 1). Akbulut et al12 reported the highest
rate (44%) of HER2 positivity in GRCC. However, in the
SEER cohort of GRCC (n=155), HER2 expression was
observed in only ∼7% of GRCC.5 Our experience (n=9) also
indicates a low HER2 protein expression in GRCCs. In
addition, HER2 gene mutations have not been reported in
GRCC.9
Two separate studies revealed EGFR activation in 2
GRCC cases, with one of the cases harboring a unique
EGFR mutation and gene ampliﬁcation.17,18 Our study,
based on NGS analysis of 5 GRCC cases, revealed no
EGFR genomic alterations in this cancer.9 ERBB3
(HER3) and ERBB4 (HER4) mutations were not detected
in GRCC either.9
MOLECULAR GENETIC CHARACTERISTICS
OF GRCC
Apart from steroid receptors and HER2/neu, the
molecular features of GRCC are largely unknown. Very
few studies speciﬁcally addressed GRCC molecular por-
traits and typically used limited technologies (summarized
in Table 2). There is no single microarray (gene expression
proﬁling) study on GRCC of the breast.
Two studies revealed a low proliferation rate of
GRCC,17,19 whereas the study of Toikkanen and Joensuu6
indicated a nondiploid nature of GRCC with a high S-phase
fraction. Another study carried out by Kim et al18 revealed a
variable Ki-67 expression in 3 GRCC cases (15-% to 60%).
Similar to other breast cancer subtypes and cancer in
general, the TP53 gene appears to be involved in a subset of
GRCCs.9,18,28 Ma et al11 reported ∼46% of GRCC cases
(n=28) to be p53 positive by immunohistochemistry. A study
by Chang et al10 also conﬁrmed a common expression of
GATA3 protein. GATA3 (=GATA Binding Protein 3) acts
as a transcription factor and is closely linked to ER function
in breast carcinoma.44 Although not speciﬁc for breast, GA-
TA3 is commonly overexpressed and is one of the most fre-
quently mutated genes in breast carcinoma.45 In a clinical
setting, GATA3 has been frequently used in the breast panel
to differentiate mammary origins from nonmammary types
of cancers. The same study also revealed HepPar1 to be
expressed in GRCC.10 HepPar1 is a useful biomarker in
detecting hepatocellular origins of the cancer cells, whereas
its expression in breast cancer has rarely been described.46 In
contrast to hepatocellular carcinomas, all GRCC were neg-
ative for alpha-fetoprotein.10
The only comprehensive theranostic study on GRCC
was carried out by our research group.9 Although limited to a
small number of tested cases, our study revealed several novel
predictive biomarkers that could guide tailored therapeutics
for patients with advanced/metastatic GRCC. The high ex-
pression of ARwithout the presence of its splice variant ARv7
indicates a rationale for treatment with anti-AR modalities.
FIGURE 1. Hematoxylin and eosin slide of a case of invasive
beast carcinoma with a predominant clear cell morphology
(>90% of cancer cells).
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Multiple studies have reported AR expression across the
breast cancer subtypes including special types and rare mor-
phologic patterns.47–49 Most of them revealed the predom-
inance of AR expression among ER-positive (luminal) breast
cancers, although up to 20% of TNBC may also overexpress
AR.50–53 Several clinical trials with anti-AR treatment mo-
dalities in AR-positive breast cancers have shown potential
therapeutic effects.48,54–57 However, ARv7 has recently
emerged as an important predictive biomarker that is fre-
quently expressed in advanced prostate carcinomas resistant
to anti-AR treatment modalities.43 ARv7 has also been re-
ported in breast cancer.58,59 However, the clinical utility of
both AR and ARv7 in breast cancer remains to be elucidated,
given that antiandrogens have not been approved yet for the
treatment of breast cancer.
A subset of GRCC was also enriched with the mo-
lecular alterations within the PIK3CA/PTEN pathway. In
particular, PTEN appears to be downregulated, even in
the absence of PTEN gene mutations.9 This may be
therapeutically relevant, given that the Food and Drug
Administration (FDA) approved Piqray (alpelisib) in
combination with fulvestrant (an ER antagonist) for the
treatment of ER+/HER2−, PIK3CA-mutated advanced/
metastatic breast carcinomas.
Given the common AR expression among the PIK3-
CA/PTEN altered GRCCs, there is a therapeutic potential
in combined treatment modalities. Thus, Lehmann et al54
recently demonstrated the therapeutic beneﬁts of combined
anti-AR enzalutamide with the PIK3CA inhibitor taselisib
in TNBC expressing AR.
The therapy with immune checkpoint inhibitors [against
programmed cell death protein 1/programmed death receptor
ligand 1 (PD-L1)] has markedly improved the treatment and
outcome of several cancers including TNBCs (IMpassion130
clinical trial, ID: NCT02425891). Several biomarkers have
been shown to have the predictive value including PD-L1
expression in cancer or immune cells, high microsatellite in-
stability (MSI) status, and high tumor mutational burden
(TMB).60,61 Most studies reported breast cancers to be MSI-
stable with low TMB and variable PD-L1 expression (more
commonly in immune cells in HER2+ and TNBC subtypes).60
In the case of breast cancer, PD-L1 expression on immune
cells has been conﬁrmed as a predictive biomarker of response
and was approved as a companion diagnostic test along with
anti-PD-L1 drug atezolizumab.60,62 The threshold for PD-L1
positivity was set at ≥1% area occupied by PD-L1+ immune
cells.63 Our study indicates the presence of PD-L1 in immune
cells (1% to 10% positivity) in a subset of GRCC, whereas
high-TMB and MSI-high were not observed in GRCC.9 This
proﬁle is similar to IBC-NST with similar molecular features
(ER+/HER2− phenotype). PTEN loss has been associated
with the resistance to immune checkpoint inhibitors.64–66 It
has been shown that PTEN downregulation may induce cy-
tokine secretion and reduce the number of TILs, thus creating
an immune-suppressive microenvironment.67 However,
PTEN loss was observed in only 1 of 3 PD-L1+ GRCC.9 On
the basis of these ﬁndings, a subset of PD-L1+ GRCCs may
be potentially eligible for the trials with immune checkpoint
inhibitors.
RADIOLOGIC AND CLINICAL
CHARACTERISTICS OF GRCC
Radiologic data on the GRCC are relatively sparse.68
Eun et al68 recently published a detailed radiologic description
of 3 GRCCs and provided an excellent review of the pre-
viously published radiologic studies on GRCC. They found
GRCC to present as a mass with irregular or oval shapes
(mammography) and as a complex cystic and/or solid mass
on ultrasound.68 Ma et al11 also reported the radiologic fea-
tures of GRCC (n=28). Similar to IBC-NST, most GRCC
presented mammographically as a high-density mass with
intratumoral calciﬁcations.11 Ultrasonography usually reveals
a hypoechoic mass with calciﬁcations.11 However, calciﬁca-
tions may not be seen and GRCCs may present as irregular,
spiculated, and hyperdense masses.68,69 Magnetic resonance
imaging ﬁndings are also similar to IBC-NST, showing ir-
regular masses with enhancement.70
The prognosis of GRCC is still controversial. Sev-
eral studies suggested that GRCC tends to follow an ag-
gressive clinical course,5,71 but other studies have indicated
that the prognosis was not signiﬁcantly different from that
of IBC-NST when matched for tumor size, grade, and
lymph node status.11,70,72,73
The most comprehensive clinical study on GRCC was
based on the SEER database.5 The study compared the clin-
icopathologic characteristics of 155 GRCC with a large cohort
(>1.2 million) of non-GRCC breast cancers. It revealed that
GRCC cases were more likely to be grade 3 carcinomas with a
triple-negative phenotype (∼45%) presenting at an advanced
clinical stage.5 Overall survival of GRCC was worse compared
with non-GRCC breast carcinomas.5 Ma et al,11 in another
study, found the number of positive axillary lymph nodes to be
a strong predictor of survival among the GRCC patients.
However, when matched with IBC-NST, the authors found no
signiﬁcant difference in survival among the GRCC patients.11
CONCLUSIONS
GRCC is an extremely rare breast cancer subtype. It
tends to be an ER-positive (∼50%), PR-negative, and
HER2-negative subtype with an unfavorable clinical outcome
compared with matched IBCs of NST. Although sparse, the
preliminary theranostic data on GRCC indicate the potential
of targeted treatments in selected cases (antiandrogen, PIK3-
CA, and immune checkpoint inhibitors). Additional molec-
ular studies that would depict its molecular characteristics are
needed. Such studies would not only enhance the knowledge
on GRCC but would also pave the way for novel treatment
modalities for this peculiar mammary malignancy.
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